Incyte cancer drug shows lasting tumor responses in some pancreatic cancer patients
In short
- Incyte's targeted drug was used alongside chemotherapy.
- The company reported lasting tumor responses in certain patients.
- The results were presented at ESMO, the European Society for Medical Oncology congress.
Why it's good news
Pancreatic cancer is among the hardest cancers to treat, so lasting responses in any patient group matter. The findings are the company's account as presented at ESMO, and the source gives no detail on patient numbers or trial stage. Readers should wait for independent review before reading more into them.
Advertisement
From STAT
A targeted drug from Incyte, when used in combination with chemotherapy, induced lasting tumor responses in certain patients with pancreatic cancer.
Ask this story
More like this
Advertisement